Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more
Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Total Assets
Latest total assets as of September 2025: CN¥9.08 Billion CNY
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) holds total assets worth CN¥9.08 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Nhwa Pharmaceutical Co Ltd - Total Assets Trend (2005–2024)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Nhwa Pharmaceutical Co Ltd's total assets of CN¥9.08 Billion consist of 71.8% current assets and 28.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.8% |
| Accounts Receivable | CN¥1.52 Billion | 18.0% |
| Inventory | CN¥661.39 Million | 7.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥394.41 Million | 4.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Nhwa Pharmaceutical Co Ltd's current assets represent 71.8% of total assets in 2024, an increase from 68.3% in 2005.
- Cash Position: Cash and equivalents constituted 16.8% of total assets in 2024, up from 13.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 5.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 18.0% of total assets.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Nhwa Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Jiangsu Nhwa Pharmaceutical Co Ltd generates 0.68x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Jiangsu Nhwa Pharmaceutical Co Ltd generates $ 13.55 in net profit.
Jiangsu Nhwa Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.29 | 6.38 | 5.77 |
| Quick Ratio | 6.32 | 5.67 | 5.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥5.74 Billion | CN¥ 5.00 Billion | CN¥ 2.74 Billion |
Jiangsu Nhwa Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Nhwa Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.97 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 15.2% |
| Total Assets | CN¥8.44 Billion |
| Market Capitalization | $1.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Nhwa Pharmaceutical Co Ltd's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jiangsu Nhwa Pharmaceutical Co Ltd's assets grew by 15.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2024)
The table below shows the annual total assets of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.44 Billion | +15.17% |
| 2023-12-31 | CN¥7.33 Billion | +13.06% |
| 2022-12-31 | CN¥6.48 Billion | +13.77% |
| 2021-12-31 | CN¥5.70 Billion | +19.98% |
| 2020-12-31 | CN¥4.75 Billion | +13.02% |
| 2019-12-31 | CN¥4.20 Billion | +4.25% |
| 2018-12-31 | CN¥4.03 Billion | +22.07% |
| 2017-12-31 | CN¥3.30 Billion | +10.98% |
| 2016-12-31 | CN¥2.97 Billion | +16.62% |
| 2015-12-31 | CN¥2.55 Billion | +32.68% |
| 2014-12-31 | CN¥1.92 Billion | +22.75% |
| 2013-12-31 | CN¥1.57 Billion | +16.47% |
| 2012-12-31 | CN¥1.34 Billion | +22.97% |
| 2011-12-31 | CN¥1.09 Billion | +14.60% |
| 2010-12-31 | CN¥954.30 Million | +22.24% |
| 2009-12-31 | CN¥780.68 Million | +7.03% |
| 2008-12-31 | CN¥729.41 Million | +22.22% |
| 2007-12-31 | CN¥596.78 Million | +18.34% |
| 2006-12-31 | CN¥504.30 Million | +4.44% |
| 2005-12-31 | CN¥482.86 Million | -- |